Viridian Therapeutics Inc
NASDAQ:VRDN

Watchlist Manager
Viridian Therapeutics Inc Logo
Viridian Therapeutics Inc
NASDAQ:VRDN
Watchlist
Price: 19.9 USD 1.43% Market Closed
Market Cap: 1.5B USD
Have any thoughts about
Viridian Therapeutics Inc?
Write Note

Wall Street
Price Targets

VRDN Price Targets Summary
Viridian Therapeutics Inc

Wall Street analysts forecast VRDN stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for VRDN is 41.44 USD with a low forecast of 22.22 USD and a high forecast of 64.05 USD.

Lowest
Price Target
22.22 USD
12% Upside
Average
Price Target
41.44 USD
108% Upside
Highest
Price Target
64.05 USD
222% Upside

VRDN Last Price Targets
Viridian Therapeutics Inc

The latest public price target was made on Nov 12, 2024 by Alex Thompson from Stifel Nicolaus , who expects VRDN stock to rise by 106% over the next 12 months. You can read more about this price target by viewing the article on StreetInsider.

Analyst Price Target Date Article
Alex Thompson
Stifel Nicolaus
41 USD
Upside 106%
1 week ago
Nov 12, 2024
Viridian Therapeutic (VRDN) PT Raised to $41 at Stifel
StreetInsider
Gregory Renza
RBC Capital
44 USD
Upside 121%
2 months ago
Sep 13, 2024
Viridian Therapeutics price target raised to $44 from $35 at RBC Capital
TheFly
Serge Belanger
Needham
38 USD
Upside 91%
2 months ago
Sep 11, 2024
Viridian Therapeutic (VRDN) PT Raised to $38 at Needham
StreetInsider
Kalpit Patel
B.Riley Financial
22 USD
Upside 11%
2 months ago
Sep 11, 2024
Viridian Therapeutic (VRDN) PT Raised to $22 at B.Riley
StreetInsider
Julian Harrison
BTIG
56 USD
Upside 181%
2 months ago
Sep 10, 2024
Viridian Therapeutic (VRDN) PT Raised to $56 at BTIG
StreetInsider
Alex Thompson
Stifel Nicolaus
40 USD
Upside 101%
2 months ago
Sep 10, 2024
Viridian Therapeutics price target raised to $40 from $33 at Stifel
TheFly
Richard Law
Goldman Sachs
25 USD
Upside 26%
3 months ago
Aug 14, 2024
Goldman Sachs Reiterates Buy Rating on Viridian Therapeutic (VRDN)
StreetInsider
Gregory Renza
RBC Capital
35 USD
Upside 76%
5 months ago
Jun 11, 2024
RBC Capital Reiterates Outperform Rating on Viridian Therapeutic (VRDN)
StreetInsider
Julian Harrison
BTIG
46 USD
Upside 131%
5 months ago
Jun 11, 2024
BTIG Reiterates Buy Rating on Viridian Therapeutic (VRDN)
StreetInsider
Andy Chen
Wolfe Research
29 USD
Upside 46%
5 months ago
Jun 10, 2024
Viridian Therapeutics initiated with an Outperform at Wolfe Research
TheFly
Richard Law
Goldman Sachs
23 USD
Upside 16%
5 months ago
Jun 6, 2024
Viridian Therapeutics initiated with a Buy at Goldman Sachs
TheFly
Leland Gershell
Oppenheimer
31 USD
Upside 56%
6 months ago
May 9, 2024
Viridian Therapeutic (VRDN) PT Lowered to $31 at Oppenheimer
StreetInsider
Douglas Tsao
H.C. Wainwright
27 USD
Upside 36%
6 months ago
May 9, 2024
Viridian Therapeutic (VRDN) PT Lowered to $27 at H.C. Wainwright
StreetInsider
Kalpit Patel
B.Riley Financial
20 USD
Upside 1%
6 months ago
May 9, 2024
B.Riley Downgrades Viridian Therapeutic (VRDN) to Neutral
StreetInsider
Show More Price Targets
Show Less Price Targets
Alex Thompson
Stifel Nicolaus
Price Target 41 USD
Upside/Downside 106%
View Source
Gregory Renza
RBC Capital
Price Target 44 USD
Upside/Downside 121%
View Source
Serge Belanger
Needham
Price Target 38 USD
Upside/Downside 91%
View Source
Kalpit Patel
B.Riley Financial
Price Target 22 USD
Upside/Downside 11%
View Source
Julian Harrison
BTIG
Price Target 56 USD
Upside/Downside 181%
View Source
Alex Thompson
Stifel Nicolaus
Price Target 40 USD
Upside/Downside 101%
View Source
Richard Law
Goldman Sachs
Price Target 25 USD
Upside/Downside 26%
View Source
Gregory Renza
RBC Capital
Price Target 35 USD
Upside/Downside 76%
View Source
Julian Harrison
BTIG
Price Target 46 USD
Upside/Downside 131%
View Source
Andy Chen
Wolfe Research
Price Target 29 USD
Upside/Downside 46%
View Source
Richard Law
Goldman Sachs
Price Target 23 USD
Upside/Downside 16%
View Source
Leland Gershell
Oppenheimer
Price Target 31 USD
Upside/Downside 56%
View Source
Douglas Tsao
H.C. Wainwright
Price Target 27 USD
Upside/Downside 36%
View Source
Kalpit Patel
B.Riley Financial
Price Target 20 USD
Upside/Downside 1%
View Source
Show More Price Targets
Show Less Price Targets
Viridian Therapeutics Inc Competitors:
Price Targets
PRQR
ProQR Therapeutics NV
89% Upside
RARE
Ultragenyx Pharmaceutical Inc
100% Upside
RPTX
Repare Therapeutics Inc
325% Upside
4593
Healios KK
91% Upside
AKBA
Akebia Therapeutics Inc
198% Upside
CCCC
C4 Therapeutics Inc
311% Upside
BAVA
Bavarian Nordic A/S
60% Upside
1672
Ascletis Pharma Inc
15% Upside

Revenue
Forecast

Revenue Estimate
Viridian Therapeutics Inc

For the last 8 years the compound annual growth rate for Viridian Therapeutics Inc's revenue is -23%. The projected CAGR for the next 3 years is 415%.

-23%
Past Growth
415%
Estimated Growth
Estimates Accuracy
-7%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Viridian Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
3%
Average Beat

Net Income
Forecast

Net Income Estimate
Viridian Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-90%
Average Miss

See Also

Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is VRDN's stock price target?
Price Target
41.44 USD

According to Wall Street analysts, the average 1-year price target for VRDN is 41.44 USD with a low forecast of 22.22 USD and a high forecast of 64.05 USD.

What is Viridian Therapeutics Inc's Revenue forecast?
Projected CAGR
415%

For the last 8 years the compound annual growth rate for Viridian Therapeutics Inc's revenue is -23%. The projected CAGR for the next 3 years is 415%.

Back to Top